1. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis
- Author
-
Matthias J. Bahr, Klaus Schulze-Osthoff, and Heike Bantel
- Subjects
Nonalcoholic steatohepatitis ,medicine.medical_specialty ,Hepatology ,Keratin-18 ,Chemistry ,Liver Diseases ,Apoptosis ,Plasma levels ,medicine.disease ,Gastroenterology ,Peptide Fragments ,Fatty Liver ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Diagnostic biomarker ,Humans ,In patient ,Apoptosis Biomarker ,Biomarkers - Abstract
2. YilmazY,DolarE,UlukayaE,AkgozS,KeskinM,KiyiciM,etal.Solubleforms of extracellular cytokeratin 18 may differentiate simple steatosisfrom nonalcoholic steatohepatitis. World J Gastroenterol 2007;13:837-844.3. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, et al. De-creased plasma levels of soluble receptor for advanced glycation endprod-ucts (sRAGE) in patients with nonalcoholic fatty liver disease. ClinBiochem 2009; doi:10.1016/j.clinbiochem.2009.02.003.4. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, et al.Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis(NASH). BMC Gastroenterol 2008;8:53.5. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M,Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008;18:1430-1437.
- Published
- 2009